CD274 and non-small cell lung carcinoma: The immune checkpoint inhibitors anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) (anti–PD-1/PD-L1) are currently changing the approach of treatment to patients with non-small cell lung cancer (NSCLC).